Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Saskia M. Brachmann, Catherine Leblanc et al.|Cancer Discovery|2022Cited by 134